Empowering inflammatory bowel disease patients with at-home remote disease and therapeutic drug monitoring

Advances in the management of inflammatory bowel disease (IBD) are opening new possibilities for at-home and patient-led care, empowering individuals to take greater control of their condition. These developments are driving the adoption of remote sampling for therapeutic drug monitoring, which complements at-home subcutaneous therapies and faecal calprotectin testing for monitoring disease activity. This article explores how these innovations could enable patients to manage their disease from home, and what this could mean for the future of IBD management.